Project Abstract Asthma is a common disease characterized by airway hyperresponsiveness (AHR) and a heterogenous inflammatory profile. In patients with asthma, comorbid obesity is associated with worse asthma control and decreased efficacy of therapy. The inflammatory profile in patients with comorbid obesity and asthma is typified by less eosinophilic inflammation and more oxidative and nitrosative (oxo-nitrosative) stress than lean patients with asthma. The mechanism of this observation is not known. However, patients with comorbid obesity and asthma have lower levels of paraoxonase 2 (PON2) in their airway epithelium than lean patients with asthma. Furthermore, PON2 levels are modulated by peroxisome proliferator-activated receptor gamma (PPAR) in multiple tissues. This proposal examines the role of changes in PON2 and PPAR in contributing to oxo- nitrosative stress in patients with comorbid obesity and asthma. Using a murine model of diet induced obesity and ozone exposure as a model of inhaled oxidative stress, this proposal will address three questions. First, what is the relationship between Pon2 expression and oxo-nitrosative stress under the condition of obesity? This question will be answered by using a high fat, high sugar diet to induce obesity and an acute ozone exposure as an exogenous oxidative insult. Pon2 expression, markers of oxo-nitrosative stress, and airway physiology will be assessed in lean and obese mice to determine if there is an association between Pon2 levels and airway oxo-nitrosative stress. These findings will be compared to Pon2-/- mice under the same conditions to isolate the effect of PON2. To isolate the precise role of the pulmonary epithelium in this process, cultured human airway epithelial cells will be exposed to ozone and assessed for oxo-nitrosative stress. Second, how does Pon2 expression changes affect the development of airway fibrosis after chronic exposure to an oxidative stressor? This question will be addressed by feeding mice either a high fat, high sugar or a control diet and then chronically exposing them to ozone for 6 weeks. At the end of six weeks, airway physiology will be measured and lung tissue will be assessed for the development of fibrosis. Third, does PPAR activation abrogate the effect of obesity on PON2 expression, AHR and markers of oxo-nitrosative stress? This question will be addressed by treating mice with the PPAR agonist, pioglitazone, and repeating the high fat, high sugar diet and acute ozone exposures from our first question. Airway physiology, PON2 levels and oxo-nitrosative stress will then be assessed.